Bristol Myers Squibb to present cardiovascular portfolio data at European Society of Cardiology Congress 2024

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 30 – September 2, 2024 in London, England. Data presented at the meeting include long-term extension data evaluating the efficacy and safety profile of CAMZYOS (mavacamten) for up to 180 weeks (3.5 years) for the treatment of New York Heart Association (NYHA) Class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM), as well as data on behalf of the BMS-Pfizer Alliance on ELIQUIS (apixaban) and the BMS-Johnson & Johnson Collaboration on milvexian.

“With the data we are presenting from our cardiovascular franchise at this year’s ESC Congress, we continue to demonstrate our long-standing and unwavering commitment to improving the lives of patients with cardiovascular disease,” said Roland Chen, MD, senior vice president and head of Immunology, Cardiovascular & Neuroscience (ICN) Development at Bristol Myers Squibb. “We look forward to demonstrating how we are advancing the development of our medicines for anticoagulation and thrombosis management and for the treatment of obstructive HCM for patients in need at the upcoming meeting.”